Biomarkers in outpatient heart failure management; are they correlated to and do they influence clinical judgment?

Netherlands Heart Journal

Volumn 22, Issue 3, 2014, Pages 115-121

  Peeters, J M P W U ^a   Sanders van Wijk, S ^a   Bektas, S ^a   Knackstedt, C ^a   Rickenbacher, P ^b   Nietlispach, F ^c,d   Handschin, R ^b   Maeder, M T ^a,e   Muzzarelli, S F ^c,f   Pfisterer, M E ^a,c   Brunner La rocca, H P ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b University Hospital Bruderholz   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f DIVISION OF CARDIOLOGY   (Switzerland)

Author keywords

Biomarkers; Cystatin C; GDF 15; Heart failure; Hs CRP; Hs TnT; Natriuretic peptide; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN T;

AGED; ANEMIA; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EDEMA; FEMALE; GENDER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

EID: 84895479701     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0503-y     Document Type: Article

References (29)

1. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585-96.
2. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13:1-207. iii.
3. Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NTproBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep). 2006; 1-147.
4. Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart. 2005;91: 1489-94.
5. Maisel A, Mueller C, Adams Jr K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-39.
6. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
7. Macheret F, Boerrigter G, McKie P, et al. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011;57:1386-95.
8. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90: 254-8.
9. Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46:118-23.
10. Frankenstein L, Remppis A, Giannitis E, et al. Biological variation of high sensitive Troponin T in stable heart failure patients with ischemic or dilated cardiomyopathy. Clin Res Cardiol. 2011;100:633-40.
11. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98: 342-50.
12. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012;17:251-61.
13. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
14. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-91.
15. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440-4.
16. Jourdain P, Funck F, Bellorini M, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur j heart fail. 2003;5:155-60.
17. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002;8:149-54.
18. Mikkelsen KV, Moller JE, Bie P, et al. Tei index and neurohormonal activation in patients with incident heart failure: serial changes and prognostic value. Eur J Heart Fail. 2006;8:599-608.
19. Piechota WN, Piechota WT, Bejm J, et al. Correlation of B type natriuretic peptides with clinical and echocardiographic parameters in heterogeneous population of patients with symptoms suggestive of heart failure. Adv Med Sci. 2006;51:164-7.
20. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-16.
21. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-9.
22. Januzzi Jr JL. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis. 2012;105:40-50.
23. Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006;151:949-55.
24. Cohen J, Cohen P. Applied multiple regression/correlation analysis for the behavioral sciences. Hillsdale: Erlbaum; 1983. p. 54.
25. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-7.
26. Maisel A. The coming of age of natriuretic peptides: the emperor does have clothes! J Am Coll Cardiol. 2006;47:61-4.
27. Krumholz HM, Baker DW, Ashton CM, et al. Evaluating quality of care for patients with heart failure. Circulation. 2000;101:E122-40.
28. Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93:476-82.
29. Mueller C, Frana B, Rodriguez D, et al. Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can J Cardiol. 2005;21:921-4.